Loading clinical trials...
Loading clinical trials...
A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the Feasibility of Home Instillation of UGN-102 for Treatment of Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate-Risk (IR) of Recurrence
Conditions
Interventions
UGN-102
Locations
5
United States
Urology Centers of Alabama (UCA)
Homewood, Alabama, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
Medication Management
Greensboro, North Carolina, United States
Urology Associates, P.C.
Nashville, Tennessee, United States
Virginia Urology
Richmond, Virginia, United States
Start Date
November 30, 2021
Primary Completion Date
February 2, 2023
Completion Date
February 2, 2023
Last Updated
September 19, 2024
NCT04235764
NCT07061964
NCT05987241
NCT00026884
NCT03375307
NCT06349642
Lead Sponsor
UroGen Pharma Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions